We are pleased to invite you to our upcoming conference, Brazil Market Potential - Biotech Event, on October 8th, 2015.
The event will feature a panel of Brazilian experts in Sao Paulo and Tel Aviv who will give real-time commercial and clinical feedback to a select number of companies. Each company selected to present, will give a short 8 minute pitch followed by 7 minutes of Q&A and feedback from the panel.
The panelists include physicians from the Albert Einstein Hospital in SP, joining us through teleconference; Avi Meizler of Meizler UCB Biopharma S.A, Ronen Hausirer a partner in Herzog Fox & Neeman's Hi-Tech Department; and other investors and commercial representatives interested in supporting the efforts of Israeli companies entering the Brazilian Market.
At the end of the event, the panel will vote for the product “most likely to succeed in Brazil.” The winning team will receive free guidance from Atche Medical on how to advance their activity in Brazil.
Presentation Criteria and Guidelines:
1) Presenting companies must have a clear definition of their product, clinical validation
and a strong commercialization plan
2) The product must be related to the Biomed Industry, preferably suited for a hospital
environment
3) We will select up to 7 companies to present at the event
4) Each presenter will have 8 minutes to present + 7 minutes of panel Q&A
5) A lottery will be held at the event to select an additional company to present
________________________________________________________________
Please provide the following information by September 7th:
- A summary of the company/product
- A short presentation – max 8 slides
Submit to: contact@israel-brazil.org
________________________________________________________________
About the Panel:
Mr Avi Meizler founded (1990) and was the President until June, 2012 of Meizler UCB Biopharma S.A. Mr. Meizler is Co-founded and CEO Advantech Bioscience Pharmaceutical Ltd, being responsible for the development of 02 biological components. Investor and Director of the board of Therapix Bioscience Ltd, Orimune Bio, Kadimastem Stem Cellss, Raziel Therapeutics, Nirolin lifescience. He has been an experienced businessman and entrepreneur in Brazil since 1979 in the fields of pharmaceuticals, engineering and construction.
Dr. Cláudio Lottenberg is a current Director at ADVANCE Medical, and was previously a Former Independent Director at Cremer SA. Dr. Lottenberg is President of the Board of Directors of Albert Einstein Hospital, ranked the #1 hospital in Latin America. Dr. Lottenberg is a former Secretary of Health for Sao Paulo. Dr. Lottenberg is one of the most well respected ophthalmologists in Brazil, and received in 2009 the Medalha Moacyr Alvaro, the most prestigious award in ophthalmology.
Mr Ronen Hausirer is a partner in the technology licensing group within the High-tech department at HFN. Specializing in commercial transactions between Israeli companies and major corporations in Asia, Europe and the U.S., Ronen advises clients from a range of industries including medical device, pharmaceuticals and bio-tech companies in a variety of transactions. Ronen specializes in technology licensing, technology transfer, general commercial transactions, joint ventures and strategic collaborations.
Albert Einstein Hospital in Brazil is the first Bone Marrow Transplantation Center in Latin America to receive FACT accreditation. HIAE is accredited for antilogous and allergenic transplantation. The hospital was founded in 1971 with the mission of providing quality health care, generating knowledge, and promoting social responsibility. In recent decades, an expansion plan doubled the hospital’s service area, expanded social programs of assistance to needy communities, and turned the hospital into a benchmark in organ transplants, in the public sector. HIAE works in close partnerships with governments for health assistance in various regions of São Paulo metropolis. The hospital’s research and educational institute has already trained approximately 130,000 professionals and conducts hundreds of studies annually.
